 Piperazines
"Piperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D010879
|
| MeSH Number(s) |
D03.383.606
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperazines".
Below are MeSH descriptors whose meaning is more specific than "Piperazines".
This graph shows the total number of publications written about "Piperazines" by people in this website by year, and whether "Piperazines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 1 | 1 | | 1993 | 2 | 1 | 3 | | 1994 | 0 | 1 | 1 | | 1995 | 0 | 2 | 2 | | 1996 | 2 | 0 | 2 | | 1997 | 0 | 1 | 1 | | 2000 | 2 | 1 | 3 | | 2001 | 1 | 1 | 2 | | 2002 | 2 | 0 | 2 | | 2003 | 1 | 2 | 3 | | 2004 | 3 | 2 | 5 | | 2005 | 7 | 4 | 11 | | 2006 | 4 | 4 | 8 | | 2007 | 11 | 3 | 14 | | 2008 | 9 | 7 | 16 | | 2009 | 11 | 3 | 14 | | 2010 | 3 | 6 | 9 | | 2011 | 7 | 4 | 11 | | 2012 | 9 | 9 | 18 | | 2013 | 3 | 6 | 9 | | 2014 | 8 | 1 | 9 | | 2015 | 3 | 7 | 10 | | 2016 | 7 | 1 | 8 | | 2017 | 4 | 3 | 7 | | 2018 | 4 | 3 | 7 | | 2019 | 7 | 5 | 12 | | 2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Piperazines" by people in Profiles.
-
Frederick BA, Gupta R, Atilano-Roque A, Su TT, Raben D. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models. Radiat Res. 2020 11 10; 194(5):519-531.
-
Dripps IJ, Bertels Z, Moye LS, Tipton AF, Siegersma K, Baca SM, Kieffer BL, Pradhan AA. Forebrain delta opioid receptors regulate the response of delta agonist in models of migraine and opioid-induced hyperalgesia. Sci Rep. 2020 10 19; 10(1):17629.
-
Watson ZL, Yamamoto TM, McMellen A, Kim H, Hughes CJ, Wheeler LJ, Post MD, Behbakht K, Bitler BG. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. Clin Epigenetics. 2019 11 27; 11(1):165.
-
Camidge DR. Next-generation ALK inhibitors: is the median the message? Lancet Respir Med. 2020 01; 8(1):5-7.
-
Pacheco JM, Byers LA. Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates? Cancer Discov. 2019 Oct; 9(10):1340-1342.
-
Dobesh PP, Bhatt SH, Trujillo TC, Glaubius K. Antidotes for reversal of direct oral anticoagulants. Pharmacol Ther. 2019 12; 204:107405.
-
Capasso A, Bagby SM, Dailey KL, Currimjee N, Yacob BW, Ionkina A, Frank JG, Kim DJ, George C, Lee YB, Benaim E, Gittleman B, Hartman SJ, Tan AC, Kim J, Pitts TM, Eckhardt SG, Tentler JJ, Diamond JR. First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits ß-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer. Mol Cancer Ther. 2019 11; 18(11):1916-1925.
-
McQueen RB, Whittington MD, Chapman RH, Kumar VM, Campbell JD. Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". Pharmacoeconomics. 2019 07; 37(7):963-964.
-
Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog. 2019 10; 58(10):1770-1782.
-
Zeller S, Wilson M, Nordstrom K. Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation. Ann Emerg Med. 2019 04; 73(4):422-423.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|